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Point mutations in cancer have been extensively studied but chromosomal gains and losses
have been more challenging to interpret due to their unspeciﬁc nature. Here we examine
high-resolution allelic imbalance (AI) landscape in 1699 colorectal cancers, 256 of which
have been whole-genome sequenced (WGSed). The imbalances pinpoint 38 genes as
plausible AI targets based on previous knowledge. Unbiased CRISPR-Cas9 knockout and
activation screens identiﬁed in total 79 genes within AI peaks regulating cell growth. Genetic
and functional data implicate loss of TP53 as a sufﬁcient driver of AI. The WGS highlights an
inﬂuence of copy number aberrations on the rate of detected somatic point mutations.
Importantly, the data reveal several associations between AI target genes, suggesting a role
for a network of lineage-determining transcription factors in colorectal tumorigenesis.
Overall, the results unravel the contribution of AI in colorectal cancer and provide a plausible
explanation why so few genes are commonly affected by point mutations in cancers.
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The so-called multistage model of carcinogenesis emerged inthe 1950s with age-dependent mortality data suggestingapproximately six to seven rate-limiting steps leading to
oncogenesis1,2. Ever since then much work has revolved around the
number and identity of somatic driver events required for genesis of
malignancy. In particular, stepwise mutations occurring in stem
cells (SCs) or progenitor cells are currently believed to be of key
importance3.
Much of the progress in cancer research has, in recent years,
emanated from high-throughput sequencing efforts that have
revealed a plethora of validated and putative driver mutations
across tumor types4,5. One unexpected lesson learned early in the
process was that frequently mutated driver genes are few6.
While the knowledge on point mutations in tumorigenesis has
expanded rapidly, the research community has somewhat
neglected the contribution of allelic imbalances (AI)—losses and
gains of genetic material often comprising whole chromosomes or
chromosome arms6. Indeed, the ﬁrst genomic analyses on solid
tumor DNA focused on detection of copy number alterations in
genomes of various cancers7. In colorectal cancer (CRC),
genome-wide copy number analyses have uncovered well-
established gross changes which include for example loss of the
loci harboring tumor suppressors TP53, PTEN, SMAD4 and APC,
and gain of MYC8. The main obstacle in AI analysis has been the
somewhat limited ability of the approach to pinpoint the main
targets of larger copy number alterations that often span whole
chromosome arms and thousands of genes similarly lost or
gained. The difﬁculty is in part inherent, as it is conceivable that a
single large ampliﬁcation or deletion can sometimes have multi-
ple targets which may be difﬁcult to distinguish with classical
genetic tools8,9. As a consequence, the contribution of gene copy
number changes in cancer has remained elusive when compared
to point mutations. We expect that current tools, when applied to
a sufﬁciently large number of lesions, provide a much improved
view on AI changes in CRC and thus enable identiﬁcation of
primary targets of gains and losses at single gene resolution.
This work provides a high-resolution data set of 1699 CRC
tumor/normal pairs pinpointing 38 genes as probable AI targets
based on previous literature, as well as insight into general fea-
tures of AI such as high relative prevalence of fragile site deletions
in microsatellite unstable (MSI) tumors and frequent formation
of isochromosome i(8q) resulting in gain of the MYC oncogene.
A long-term cell culture assay of normal and TP53 knockout cell
lines demonstrated sufﬁciency of this common tumor suppressor
deletion for generation of large scale AI in vivo. We further
studied the hundreds of candidate AI target genes by replicating
the AI analysis, demonstrating the direct effects of AI on gene
expression in 259 additional CRCs10 and by testing their effect on
proliferation in CRISPR/Cas9 and CRISPRa/dCas9 CRC cell line
screens. The relationship of AI and point mutations was studied
by whole-genome sequencing (WGS) 256 of the tumor/normal
pairs. This revealed a subtle effect of DNA copy number on the
somatic mutation detection rate. Importantly, AI events clearly
outnumbered somatic point mutations even in known cancer
genes. Finally, we examined correlations between the copy
number aberrations at those 37 peaks that harbored curated
cancer genes and studied their functional genomics with ChIP-
nexus/exo, siRNA and RNA-seq assays. This data revealed a
network of lineage determining transcription factors (TF) con-
verging in activation of the MYC oncogene.
Results
High-resolution allelic imbalance analysis reveals CRC drivers.
We studied AI in a set of 1699 CRC tumor/normal DNA pairs
extracted from fresh-frozen tissue or blood. In cancer DNA, we
evaluated AI at loci found to be heterozygous in the corresponding
normal sample—2.5 million single nucleotide polymorphisms
(SNPs) measured for B-allele frequency (BAF)—and classiﬁed the,
often large, continuous segments of equally imbalanced SNPs into
losses and gains based on mean log R ratio (LRR)11. The two alleles
at the heterozygous loci provide a perfect control for allelic relative
copy number, resulting in much higher sensitivity for detecting
chromosomal changes as compared to analysis based on LRR alone.
We separately counted the tumors with either allelic gain or
loss on every locus of the genome (“loss” refers here also to copy
number neutral loss of heterozygosity (LOH)). The resulting
graphs were smoothed in 10 breakpoint rolling windows and the
local maxima in the smoothed graph were called as peaks
(Fig. 1b). The peaks were scored according to their prominence
(the height of the peak above the lowest contour line that
surrounds it and does not contain a higher peak). In total, we
identiﬁed 165 peaks whose prominence was at least 15 tumors
(Supplementary Data 1). The large number of studied CRCs and
the sensitive nature of allelic imbalance analysis as compared with
copy number analysis provided a high spatial resolution for
pinpointing target genes (Fig. 1, Supplementary Figure 1). While
the losses and gains in a single tumor typically affected very large
chromosomal segments, the areas of local maxima—peaks—were
narrow due to the large number of tumors analyzed. Most often
these contained only one protein coding gene (Fig. 1a).
The list of 106 loss and 59 gain AI peaks was curated based on
previous literature in order to identify plausible candidate genes
relevant for somatic selection. We found a strong candidate gene
for 17 gain and 18 loss AI peaks (Table 1). These peaks contain
well-known CRC genes such as APC, TCF7L2, andMYC, and also
several genes with direct therapeutic relevance such as KRAS,
ERBB2, FGFR1, and PDGFRB12. One peak included two plausible
driver genes, PDGFRB and CDX1 at 5q, and some had a likely
target just outside the region, such as the tumor suppressor TP53
of which the coding sequence locates 17 kb from a peak in
chromosome 17p (Supplementary Figure 2).
Additionally, we called balanced copy number aberrations to
detect areas of clonal homozygous loss. Compatible with previous
reports9, these were few. Recurrent homozygous losses were
detected only at chromosomal fragile sites, and at the tumor
suppressors PTEN and SMAD4. Thus, altogether 38 genes in 37
peaks were highlighted in our analysis; 36 by AI and 2 by
homozygous loss.
The three most common loci of loss in the whole data set were
TP53 in 1072 or 63% of 1699 cancers, SMAD4 (1040 or 61%) and
8p21.3 (806 or 47%) (Table 1). The three most frequently gained
loci in the whole data set were HNF4A in 803 or 47% of 1699
cancers, KLF5 (709 or 42%) and MYC (585 or 34%) (Fig. 1b), all
of which have previously been implicated as ampliﬁcation targets
in CRC8,13,14. Our data provide high-resolution genetic validation
of these genes as frequent drivers of CRC.
MSI CRCs are chromosomally stable, except for fragile sites.
Microsatellite stable (MSS) CRCs harbored 3.9-fold more allelic
imbalance (by basepairs covered) than MSI CRCs. MSS cancers
also showed strong preference of TP53 and SMAD4 losses (gen-
ome-wide-corrected logistic model, p < 10−5), whereas aberra-
tions in MSI CRCs occurred preferably at common fragile sites
FHIT (Logistic model, p < 10−5), RBFOX1 (p < 10−5), WWOX
(p < 0.02), and MACROD2 (p < 0.05) (Supplementary Table 1).
8p is commonly lost through formation of isochromosome i
(8q). Loss of chromosome arm 8p is the third most common AI
alteration in our data, occurring in almost half (47%) of the
cancers examined. Frequent loss of chromosome 8p has been
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ﬁrmly linked to colorectal tumorigenesis for decades15, but the
identity of the possible target genes has remained elusive.
Genome-wide inspection of correlations between gains and losses
within chromosomes revealed that 8p loss and MYC gain (in 8q)
co-occurred in the same samples (OR= 3.9, p < 3.3 × 10−29,
Fisher’s exact test, Fig. 1c). Furthermore, analysis of WGS data
revealed frequent chromosome 8 AI and copy number changes
co-occurring with sequence inversion in the pericentric region in
the p-arm of the chromosome. This signals formation of iso-
chromosome i(8q) with two centromeres and q arms and a small,
duplicated and inverted segment of the p-arm (Fig. 1d)16. In total
409 tumors (24%) appear to have undergone isochromosome i
(8q) formation (Methods), gaining a copy of 8q (including
oncogene MYC) and losing a copy of 8p in a single chromosomal
event.
Mutant KRAS locus is commonly low level gained in CRC. One
of the curated gain targets, KRAS, is often activated by somatic
mutations and there have been reports of exclusivity of KRAS
ampliﬁcation and mutation17. We Sanger sequenced the KRAS
gene in 1447 of our samples and correlated the point mutation
and the copy number statuses at the KRAS locus in these tumors.
While 31% (279/893) of the samples with no AI at KRAS had a
somatic point mutation, 72% (129/178) of the samples with copy
number gain AI at KRAS did have a mutation. The raw LRR
values at the KRAS locus reveal also a small subset of wild type
samples with strong ampliﬁcation (Supplementary Figure 3).
Gene expression levels reﬂect copy numbers. AI analysis was
repeated in an additional set of 259 colorectal tumors, and pre-
viously generated RNA-seq data10 from these tumors was ana-
lyzed for a potential association between AI copy number and
gene expression (see Methods). As expected, the majority of the
curated AI peak genes displayed signiﬁcant association between
the copy-number variation at the AI peak and gene expression
(Wald test, Benjamini–Hochberg FDR < 10%, Table 1, Supple-
mentary Figure 4, Supplementary Table 2 and Supplementary
Data 3).
Furthermore, to connect the functional effects of chromosomal
changes to overall patient survival, we analyzed whether genes
whose expression is associated with a favorable or unfavorable
prognosis18 are on average gained or lost in our data.
Interestingly, the genes whose expression is associated with
favorable prognosis are lost more often than genes associated with
unfavorable prognosis (p < 10−24 Mann–Whitney U-test). Con-
versely, the genes associated with unfavorable prognosis are
gained more often than genes associated with favorable prognosis
(p < 10−11, Mann–Whitney U-test). Although the list of favor-
able/unfavorable genes is not controlled for copy-number and
thus contains abundance of passengers, the clinical effect is also
reﬂected in our data as a slight survival advantage for patients
with low amount of AI (p= 0.02, Kaplan–Meier log-rank test,
Supplementary Figure 5).
High copy number regions host more single base substitutions.
Next we analyzed the relationship of somatic copy number
changes and single-nucleotide variants (SNV) that were detected
in the same samples. WGS data were generated from a subset of
the 1699 CRCs consisting of 234 microsatellite stable (MSS)
tumors and their respective normal tissues. Analysis of the reg-
ulatory genome (noncoding) mutations of 213 of these has been
published previously19. We observed that the density of SNVs
increase with the LRR copy number measure (Fig. 2a). The
clonality of the SNVs is nearly uniform as long as there is more
than one chromosome copy present in the tumor (Fig. 2b). Also
the median count of the mutated reads on a given SNV is mostly
independent of copy number (Fig. 2c), suggesting that the
increased rate of SNVs is not only due to improved detection
sensitivity but displays increased mutation density at high copy
number regions. These data are compatible with a neutral model
of somatic mutations where each chromosomal copy obtains
somatic mutations independently with constant rate per repli-
cated base pair.
Frequent large scale copy number aberrations cast doubt on
some tools for identifying cancer genes if the underlying copy
number is not accounted for as a source of background mutation
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rate variation20. For example MutSig2CV p-values for gene
mutation signiﬁcance in the TCGA colorectal cancer project have
a negative correlation with the mean LRR in the samples in this
study (Supplementary Figure 6)4. Similarly, driver p-values from
20/20+ analysis of pancancer data are slightly smaller in high
rather than low copy number regions20 (Supplementary Figure 7).
The copy number bias does not seem to similarly affect
OncodriveFML21, which models mutation likelihoods in local
genomic context (Supplementary Figure 8).
Most cancer genes have higher prevalence of AI than SNVs.
Using OncodriveFML21, we identiﬁed a total of 42 genes targeted
by signiﬁcant numbers of somatic point mutations in the set of
234 whole genome sequenced MSS tumors (OncodriveFML,
Benjamini-Hochberg FDR < 10%, Supplementary Table 3, Sup-
plementary Figure 9). Analysis of the mutation burden in these 42
genes, and 42 genes associated with CRC in the COSMIC cancer
gene census (total of 74 unique genes), showed that the point
mutation rate in MSS tumors rivaled the rate of respective
chromosomal aberrations in only APC, KRAS, and TP53
(Supplementary Figure 10). The median value of cancer gene
point mutations per tumor was 5 (Fig. 3a, Supplementary
Table 4), whereas a median of 10 curated peak loci displayed
expected type (gain for oncogenes in gain type peaks, loss for
tumor suppressors in loss type peaks) of AI in each tumor
(Fig. 3b). These results highlight the major role of AI in CRC even
considering that a subset of AI events hitting cancer genes are
likely to be random.
TP53 loss enables allelic imbalance in normal cells. Evaluating
the clonality of the curated loss peaks with the tumor purity
corrected B-allele frequency (cBAF) revealed that TP53 had the
highest mean clonality of all peaks, followed by APC, SMAD4,
and SOX9 (Supplementary Figure 11). This is compatible with
relatively uniform presence of these gene defects in cells forming
the surgically removed tumor. We probed the role of TP53 loss in
downstream mutational processes as this gene has been widely
accepted as the “guardian of the genome”22. We cultured wild
type normal human RPE1 cells and three clonal RPE1 TP53-null
lines23 for 6 months in parallel. In whole-genome sequencing of
Table 1 Literature curated 37 AI peak loci
Gene Location AI type Protein coding genes in
peak
CRCs with AI MSS CRCs with SNV or indel at target
gene
Annotation
TP53 17p Loss 2 1076 (63%) 148 (63%) S.E
SMAD4 18q Loss 5 1054 (61%) 27 (11%) STE
HNF4A 20q Gain 5 804 (47%) 3 (1%) STE
APC 5q Loss 1 764 (45%) 179 (76%) STE
KLF5 13q Gain 1 709 (42%) 5 (2%) STE
USP12 13q Gain 0 694 (41%) 0 (0%) .TE
RUNX3 1p Loss 2 678 (40%) 3 (1%) …
TLR3 4q Loss 4 642 (38%) 7 (2%) ..E
SOX9 17q Loss 0 621 (36%) 11 (4%) STE
MYC 8q Gain 1 585 (34%) 1 (0%) STE
BMPR1A 10q Loss 4 581 (34%) 3 (1%) ..E
PTEN 10q Loss 5 581 (34%) 9 (4%) STE
FGFR3 4p Loss 3 551 (32%) 1 (0%) S.E
TCF7L2 10q Loss 1 548 (32%) 21 (8%) STE
PARK2 6q Loss 1 545 (33%) 8 (3%) ST.
NCOR2 12q Loss 1 495 (29%) 5 (2%) S.E
GPRC5A 12p Loss 3 495 (29%) 0 (0%) STE
SMARCA2 9p Loss 0 440 (26%) 5 (2%) .TE
CDKN2B 9p Loss 0 437 (26%) 0 (0%) ST.
RHOB 2p Loss 1 433 (26%) 0 (0%) ..E
ACVR2A 2q Loss 3 430 (25%) 7 (3%) S.E
MLK4 1q Loss 2 428 (25%) 0 (0%) S.E
G0S2 1q Loss 9 408 (24%) 0 (0%) S..
CTCF 16q Loss 13 387 (23%) 3 (1%) S.E
FGFR1 8p Gain 2 254 (15%) 6 (2%) S..
CCND2 12p Gain 1 186 (11%) 0 (0%) STE
KRAS 12p Gain 4 179 (11%) 121 (51%) ..E
IGF2 11p Gain 4 126 (7%) 0 (0%) STE
BPTF 17q Gain 5 110 (6%) 9 (3%) STE
NOTCH1 9q Gain 4 101 (6%) 4 (1%) ..E
ERBB2 17q Gain 14 99 (6%) 10 (4%) STE
SATB2 2q Gain 1 83 (5%) 4 (2%) .TE
PDGFRB, CDX1 5q Gain 6 69 (4%) 5 (2%) …, ..E
ITGB1 10p Gain 3 56 (3%) 0 (0%) S.E
FOXA1 14q Gain 4 48 (3%) 1 (0%) S.E
TNFAIP2 14q Gain 11 36 (2%) 1 (0%) …
DGCR8 22q Gain 11 32 (2%) 0 (0%) ..E
If the number of protein coding genes in a smoothened peak area was zero, the two ﬂanking genes were considered as candidate targets. Gene names are in bold if they have not been previously reported
as high-resolution (identiﬁed area containing 10 or fewer genes) AI target in CRC. Type of gross change at the target is indicated as “Loss” or “Gain”. The number of tumors with AI, including the
homozygous losses at PTEN and SMAD4, are shown for 1699 CRCs. The number of tumors with somatic nonsynonymous SNVs and indels in the presumed AI target gene is given for the subset of 234
MSS tumors that underwent WGS. Peaks are annotated by re-discovery in the two lower-resolution datasets, 230 Danish colorectal cancers (S) and TCGA COADREAD (n= 573) (T), and signiﬁcant
expression change (FDR < 10%) (E). Citations in Supplementary Data 2
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the four lines the TP53-null cells displayed a weak, not statistically
signiﬁcant 23–46% increase in single-nucleotide variants (SNVs)
(p= 0.08, negative binomial, Supplementary Table 5, Supple-
mentary Figure 12), compared to the TP53 wild-type line. The
TP53-wild type control and one of the mutant lines (KO3) did
not show any novel allelic imbalances. However, two of the TP53-
null lines displayed striking allelic imbalances in two (KO17) and
twelve (KO6) whole chromosomes. RNA-seq of the cultured cells
revealed high median expression of genes on the balanced
chromosomes of KO6, suggesting a biallelic genome duplication
followed by a series of chromosomal losses, producing a cell with
three (imbalanced) or four (balanced) copies of each chromo-
some. The chromosomal aberrations were large, with no trace of
chromothripsis.
To further validate the high rate and diversity of AI events in
TP53-null cells, we applied SNP array genotyping to two clonal
lines (KO6.2 and KO17.3) separated from KO6 and KO17 by
2 weeks of culture. These lines showed additional AI on two
(KO17.3) and one (KO6.2) chromosomes. A similar effect was
detected in the primary tumor samples (Fig. 3b and Supplemen-
tary Figure 13). Taken together these data demonstrate that TP53
deﬁciency is sufﬁcient for the cell to tolerate aberrant gene dosage
and thus facilitates accumulation of tumorigenic copy number
changes.
CRISPR screens reveal role of AI genes on cancer cell growth.
In order to identify the AI target genes within the 165 AI peaks
we systematically probed the 927 protein coding genes residing in
the identiﬁed peak areas—including six ﬂanking genes for each
peak—for their potential role in CRC cell proliferation. This was
done by 33-day long pooled CRISPR/Cas9 knockout24 and
CRISPRa/Cas9d activation screens25 in three CRC cell lines,
GP5d, COLO320DM and CaCO2 (Supplementary Figure 14,
Supplementary Data 4 and 5). These assays detect genes whose
loss or overexpression increases or decreases growth of tumor
cells in culture.
In the loss-of-function CRISPR/Cas9 screen, several genes with
a known CRC regulatory role such asMYC, KLF5, CCND2, BPTF,
TCF7L2, CTCF, and SMAD4 together with 58 other genes, were
identiﬁed as required for cell growth in at least one of the three
cell lines (Robust Rank Aggregation, FDR < 0.1). Copy number
status of the cell line can have a strong inﬂuence on the CRISPR/
Cas9 results26 but in our case the effect was limited to at most ﬁve
genes for which the loss-of-function phenotype was detected only
in a cell line where the gene is located in a copy-number-gained
region (Supplementary Methods, Supplementary Data 4). Among
the genes required for growth was also BPTF, a cancer gene less
studied in CRC. As expected, growth inhibitory genes (loss
promotes growth) were detected more rarely; only PTEN was
identiﬁed in two cell lines, 5 other genes in one. A growth
phenotype was detected in at least one of the cell lines for 71
genes located in 45 peak areas in total. These genes serve as
additional AI target candidates.
The results of our loss of function screen were highly consistent
with the results obtained in other CRC cell lines screened
genome-wide but using fewer guide RNAs per gene by the Cancer
Dependency Map Project27. From the 795 genes in AI peak areas
that were measured by both, the twelve genes whose knock-out
had the largest negative effect on growth across CRC lines in their
screen were all identiﬁed as being required for cell growth in at
least one cell line in our screen (Hypergeometric p < 10−13,
Supplementary Figure 15, Supplementary Data 4). Conversely,
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the 61 genes identiﬁed in our screen as required for cell growth
for at least one cell line had a median rank of 62 in their screen
within the 795 shared genes (Mann-Whitney U, p < 10−23). More
generally, the genome-wide results highlight the particular
importance of the AI target genes for CRC: of the 17,670 genes
measured, six of the top ten genes that the CRC cell lines were
particularly dependent on (versus other cancer cell lines) were in
the AI peaks: TCF7L2, SATB2, KRAS, KLF5, CCND2, and DBF4
(Fisher’s exact test p < 2 × 10−7).
The gain of function CRISPRa/dCAS9 experiment found a
growth phenotype for 9 genes (Supplementary Data 5). Activa-
tion of PDGFRB, PIGQ, and MYC (and as a likely bystander its
adjacent gene CASC11), increased cell growth while activation of
SOX9, IKZF3, IRF6, RASAL2, and KRAS inhibited growth.
Notably, only COLO320DM growth was promoted by activation
of MYC, which is already >60× ampliﬁed in its genome and was
the only hit in the activation screen with copy number alteration
in the tested cell line. Also worth noting, GP5d growth was
inhibited by activation of KRAS-G12D, while KRAS activation in
wild type cell lines (CaCO2, COLO320DM) did not have a
detectable effect.
The only shared hit between knockout and activation screens
was MYC, further highlighting its central role in CRC cell
proliferation.
TFs in AI peaks co-operate toward MYC activation. We
examined interchromosomal correlations between the copy
number aberrations at the 37 peaks with curated genes. All sig-
niﬁcant associations (Logistic regression, Bonferroni-corrected
p < 0.05. Supplementary Methods) observed are depicted in
Supplementary Figure 16. A particularly striking ﬁnding is a
clique of transcription factors that tend to display AI in the same
samples (Fig. 4a). To ﬁnd possible loops of aberrant regulation
within the clique, we studied the target genes and DNA binding
patterns of FOXA1, HNF4A, KLF5, MYC, and TCF7L2 tran-
scription factors (Supplementary Figure 17 and Tables 6-9). We
performed ChIP-nexus/exo binding assays and siRNA knock-
down followed by RNA-seq in three (LoVo, GP5d,
COLO320DM) colon cancer cell lines. Direct target genes of TFs
were searched from the same topologically associated domains28
in which ChIP-nexus/exo peaks were identiﬁed. To detect up- or
downregulated genes after siRNA knockout of the TFs, we used
sleuth29 to compare RNA-seq data from perturbed experiments
to the control (non-targeting siRNA) experiment. Furthermore,
expression of each TF was studied in 259 colorectal tumor
RNA-seq data with a regression model including LRR of the
target TF, expression levels of the other four TFs and tumor
purity as predictors. These experiments, summarized in Fig. 4b,
provided evidence for formation of a regulatory loop between
some of the key factors that converged on regulation of the MYC
oncogene (Supplementary Data 6 and 7 and Supplementary
Table 10).
Discussion
We hypothesized that the principal targets of both chromosomal
gains and losses could be determined at a gene level resolution
through genetic analysis if enough data for a speciﬁc tumor type
was available. While our current effort was extensive, improved
resolution of events—in particular those that are relatively rare
(Table 1)—can be anticipated as the amount of high-quality data
accumulates and reaches thousands of samples. Our data pre-
cisely identify 38 plausible targets in total, 18 for gain and 20 for
loss. In our study, the “loss” category also includes copy number
neutral loss; such a change can equally ﬂag selection of either
hypoactive or hyperactive alleles. To our knowledge, 26 of the 38
genes have not been reported as high-resolution targets for AI in
CRC (Table 1). In low-resolution studies, a very large number of
genes have been reported to be lost/gained but the highly
unspeciﬁc nature of such information has not always served well
the efforts to understand the disease. As expected, MSI CRCs
were in general much more chromosomally stable than MSS
tumors. However, deletions at fragile sites were as frequent in
a
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MYC
TP53
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*
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*
*
Concordant with CRC tissue
Detected by RNAi
Detected by RNAi and ChIP
Gene
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Fig. 4 Functional genomics scrutiny of associations between curated TF hits. a Curated AI peaks that contained key TFs associated with each other. Oval
and rectangle nodes represent loss and gain peaks, respectively. An edge is drawn between nodes if genome wide corrected association p-value < 0.001
(logistic regression). Width of edge is proportional to effect size. All edges represent positive association. b Regulatory circuitry of the transcription factor
targets of AI. siRNA silencing followed by RNA-seq were used to detect positive and negative regulatory relations between TFs with FDR < 0.05 (Wald
test). Red edges detected in GP5d cell line, orange in LoVo, purple in both. Asterisks depict concordant expression relation between the pair of TFs (FDR <
0.05) in the regression analysis of RNA-seq data from 259 colorectal tumors as compared to siRNA experiments (details in Supplementary Methods).
Thick lines show potentially direct regulation based on the presence of the corresponding ChIP-nexus/exo peaks. Note that the cell lines tested displayed
different regulatory states of the network, but the MYC gene was essential in all, based on the CRISPR/Cas9 screen, suggesting that individual tumors
utilize different upstream mechanisms to drive cell growth through MYC39
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MSI as in MSS CRCs. The mechanisms causing chromosomal
changes at fragile sites appear to be shared in MSI and MSS
CRCs, and are probably different from the forces driving chro-
mosomal instability elsewhere.
The most common AI event with no obvious candidate target
was loss at 8p21.3, affecting 806 (47%) of 1699 cancers examined.
Importantly, we concluded that loss of the 8p-arm typically
occurred through a single chromosome 8 event leading to 8q
isochromosomes and concomitant gain of MYC and loss of 8p as
seen from the WGS data. Thus frequent loss of 8p in CRC may at
least in part be a passenger event, driven by the strong positive
selective value of MYC gain.
AI at the KRAS locus was strongly associated with presence of
an activating mutation, providing an example of co-operation
between chromosomal gross changes and base level events. High-
level ampliﬁcations were only seen in KRAS wild-type lesions,
compatible with possible adverse cellular effects of too much
KRAS activity. Evidence for this was also seen in the CRISPRa
screen where further activation of mutant KRAS was found to be
detrimental. The genetic and CRISPRa data are consistent with
three different routes of KRAS activation, either through KRAS
point mutation with or without gain of the mutant allele, or
through strong ampliﬁcation of wild-type KRAS. Whether the
different states affect response to treatment is worth further study.
When analysing the relationship between somatic copy num-
ber changes and SNVs, we observed an increase in the density of
SNVs with increasing copy number (Fig. 2a). Each chromosomal
copy appears to obtain somatic mutations independently with
constant per base pair rate. The effect of high copy number
regions accumulating increased numbers of mutation calls causes
a bias in many NGS analysis approaches, and should be taken
into account in the future.
Our data draw a picture where allelic imbalance (enabled e.g. by
TP53 defect) introduces a high number of aberrations in key genes
involved in control of lineage development and cellular growth
resulting in poor patient survival. The results highlight the impor-
tance of aberrations in intestinal stem cell homeostasis in colorectal
carcinogenesis as several key genes encoding factors known to be
involved in its maintenance were located at frequently targeted
regions: HNF4A, APC, RUNX3, NOTCH1, KLF5, SOX9, BMPR1A,
TCF7L2, and CDX130,31. One emerging hypothesis from our data is
that AI contributes to the establishment of positive and dynamic
regulatory loops between key transcription factors; loops that are
selected for due to resulting aberrant cellular homeostasis that either
increases the risk of secondary tumorigenic events, or directly
maintains the cancer phenotype. The networks are connected to the
cell growth machinery via the MYC oncogene, which itself is an AI
target and essential for growth of all of the cell lines analyzed here.
Based on the differential requirement of some of the AI target genes
for cell growth in the CRISPR/Cas9 screen, and the fact that dif-
ferent tumors often harbor different AI events and mutations, it
appears that individual tumors achieve a similar locked gene reg-
ulatory state that drives MYC expression and cell growth via dif-
ferent upstream AI events, somatic mutations and/or ampliﬁcation
of MYC itself. AI-driven regulatory mechanisms may also be
adjustable to the changing requirements of neoplastic progression.
For example, frequent losses at SOX9 (seen in more than one third
of all samples, Table 1) and the observed growth inhibition in the
CRISPRa assay are compatible with selection of reduced SOX9
expression while the gene was consistently overexpressed in the
RNA-seq data from the surgically removed full-blown cancers in
both cases with AI, as well as those without (Supplementary Fig-
ure 18). Overall, the data suggest that the selection pressure on
SOX9 expression varies in direction during different stages of tumor
development.
The signiﬁcant potential of AI in developing genetic aberra-
tions (Fig. 3) provides a plausible explanation why so few genes
are commonly mutated in most cancers. Not many genes are
likely to be so important for malignant transformation that their
ﬁxed point mutations are frequently selected for. Instead, during
tumorigenesis, preference can be envisioned for gross chromo-
somal changes affecting expression levels of the main targets and
multiple other genes through a single event, while still retaining
ﬂexibility to the changing needs of the neoplastic process. Given
the prevalence of the AI events, robust knowledge of the main AI
targets and the contexts in which they are active in tumorigenesis
is essential for understanding cancer. Our data warrant serious
consideration when designing functional experiments modeling
different aspects of cancer gene interplay, as well as examining
responses to therapy. The next straightforward step is to robustly
identify the main targets of gene dosage aberrations across all
tumor types. Compilation of such knowledge should be an
important near-term goal for cancer genomics research. The
current work demonstrates how accumulation of dense genetic
data from thousands of lesions of a given type, and paired normal
tissue, produces accurate catalogs of highly relevant genes to be
coherently evaluated as important pieces in the puzzle of cancer.
Methods
Samples. The study has been reviewed and approved by the Ethics Committee of
the Hospital District of Helsinki and Uusimaa (HUS). Signed informed consent or
authorization from the National Supervisory Authority for Welfare and Health has
been obtained for all Finnish sample materials used. The use of the Danish tissue
samples was approved by the Central Denmark Region Committees on Biomedical
Research Ethics. Informed written consent was provided by all Danish participants.
Genotyping and AI analysis. The tumor and respective normal DNA samples
were genotyped with Inﬁnium Omni2.5-8 (Illumina Inc.) array at Estonian Gen-
ome Center. The B-Allele Frequencies and Log-R ratios were extracted with Illu-
mina Genome Studio software and the allelic imbalance regions were calculated for
all samples using BAFsegmentation11 with default parameters. AI count graph was
generated by counting tumors with AI on particular locus using bedtools geno-
mecov32 separately for gains and losses. The AI count graph was smoothed with
max function in a window of 10 consecutive breakpoints. Peaks were called as local
maxima of the smoothed AI count graph. Peaks were ranked according to their
topographic prominence, the height of the peak above the lowest contour line that
surrounds it and does not contain a higher peak, in the unsmoothed AI graph. The
highest peak of a chromosome has prominence equal to its height. The peaks with
prominence of at least 15 were reported. A tumor sample was called as having an
isochromosome if at least 80% of at least one chromosome arm is called allelic
imbalance and the mean LRR on the p-arm is at least 0.2 less than on the q-arm.
The 259 Danish tumor samples were genotyped and analyzed with same the
methods except the germline heterozygous sites were obtained from prior
genotyping10.
Phenotype and cross-peak associations were studied with logistic regression
controlling for the sum of the lengths of AI regions on chromosomes other than
chromosome of the studied peak(s).
Whole-genome sequencing. Sequencing of 256 CRC and respective normal
samples was carried out with an Illumina HiSeq 2000 and HiSeq X10 (Illumina Inc,
and SciLifeLab) using a paired-end sequencing protocol. Read length was 100 bp.
TF binding and RNA-seq. ChIP-nexus, -exo, and -seq was performed as described
previously33–35. Experimental details and antibodies used are listed in Supple-
mentary Methods.
LoVo, GP5d, and COLO320DM cell lines were treated in triplicates with
human ON-TARGETplus siRNA smartpools (GE Dharmacon) to silence each of
the 38 AI target genes individually and their gene expression was measured with
RNA-seq. The expression was quantiﬁed with Kallisto36 and analyzed with
Sleuth29.
CRISPr screens. For CRISPko screen, guide RNAs (gRNAs) were designed to
target the ﬁrst and second exons of 1928 candidate target genes in AI regions and
198 control genes. For CRISPRa, the gRNAs target the ﬁrst 200 bp upstream of
each TSS as previously suggested. 2 × 2 × 12472 sgRNA oligonucleotides (96–102
nucleotides) were ordered from CustomArray for both CRISPRko and CRISPRa
screens. A minimum of 40 million Cas9 or dCas9 expressing GP5d, COLO320DM
or CaCO2 cells were transduced (MOI 1) with lentivirus pool containing sgRNA
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libraries. First timepoint sub-culturing was performed 4 days after transduction.
Cells were grown for 33 days after transduction with sub-culturing being per-
formed every 4–6 days. Screens in all cell lines were performed as duplicates.
The gene level signiﬁcance in the CRISPR screens was evaluated using Robust
Rank Aggregation37
All genomic coordinates are reported in GRCh37 assembly. The custom
software used is available from the authors. Further method details are available in
the Supplementary Methods.
Data availability
The sequence data are available from ENA accession PRJEB25645 and EGA accessions
EGAS00001002966, EGAS00001003010. Per sample AI regions, CRISPr/Cas9, CRISPRa
guide designs and RNAi-RNA-seq analysis results are available in Zenondo repository
https://doi.org/10.5281/zenodo.1222172. All other remaining data are available within
the Article and Supplementary Files, or available from the authors upon request.
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